BIO vs OSUR
BIO: A multinational life science and clinical diagnostics company providing research tools, diagnostic test systems, and consumables to laboratories and biopharmaceutical manufacturers worldwide. OSUR: OrasuRe is a diagnostic company specializing in rapid point-of-care and self-test solutions for infectious diseases and rare conditions, with recent expansion into sickle cell screening through the BioMedomics acquisition.
Side-by-side fundamentals
| Metric | BIO | OSUR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $305.96 | $3.79 | |
| Market cap as of 2026-07-23 | $8.2B | $262M | |
| P/E as of 2026-07-23 | 48.82 | n/a | |
| PEG as of 2026-07-23 | n/a | -0.03 | |
| Net margin as of 2026-07-23 | +6.5% | -66.4% | BIO higher |
| Gross margin as of 2026-07-23 | +51.8% | +42.5% | BIO higher |
| Operating margin as of 2026-07-23 | +2.0% | -68.6% | BIO higher |
| ROE as of 2026-07-23 | +2.4% | -21.5% | BIO higher |
| ROA as of 2026-07-23 | +1.7% | -18.2% | BIO higher |
| Debt / equity as of 2026-07-23 | 0.18 | 0.00 | OSUR lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.9% | -30.1% | BIO higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | -33.3% | BIO higher |
| Beta as of 2026-07-23 | 1.06 | 1.03 | |
| 1-year return as of 2026-07-22 close | +24.6% | +9.9% | BIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.